创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06628 创胜集团医药-B

未开盘 09-03 16:08:19

1.010

-0.055

-5.16%

最高1.055	最低0.980	成交量107.00万
今开1.055	昨收1.065	日振幅7.04%
总市值4.58亿	流通市值4.58亿	总股本4.53亿
成交额108.33万	换手率0.24%	流通股本4.53亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06628","market":"HK","secType":"STK","nameCN":"创胜集团医药-B","latestPrice":1.01,"timestamp":1788422899279,"preClose":1.065,"halted":0,"volume":1070000,"delay":0,"changeRate":-0.05164319248826286,"floatShares":453000000,"shares":453000000,"eps":-0.49,"marketStatus":"未开盘","change":-0.055,"latestTime":"09-03 16:08:19","open":1.055,"high":1.055,"low":0.98,"amount":1083345,"amplitude":0.070423,"askPrice":1.05,"askSize":4500,"bidPrice":1.01,"bidSize":4000,"shortable":0,"etf":0,"ttmEps":-0.41,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":0,"adr":0,"listingDate":1632844800000,"exchange":"SEHK","adjPreClose":1.065,"openAndCloseTimeList":[[1788399000000,1788408000000],[1788411600000,1788422400000]],"volumeRatio":5.166586186753636,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06628","defaultTab":"news","newsList":[{"id":"2663309068","title":"创胜集团医药-B(06628.HK)：程根宏获委任为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2663309068","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663309068?lang=zh_cn&edition=full","pubTime":"2026-08-29 01:04","pubTimestamp":1787936651,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06628","BK1161","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176261525","title":"创胜集团医药-B（06628）公布最新董事会及下设委员会成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1176261525","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176261525?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:59","pubTimestamp":1787929144,"startTime":"0","endTime":"0","summary":"2026年8月28日，创胜集团医药-B在公告中披露公司董事会及其下设委员会最新成员组成，具体如下：。公告显示，公司董事会及各专门委员会的最新组成自公告日期起生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128401392","title":"创胜集团医药-B（06628）宣布2026年8月委任新独董并发放3万股奖励股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1128401392","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128401392?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:55","pubTimestamp":1787928940,"startTime":"0","endTime":"0","summary":"创胜集团医药-B8月28日公告，公司董事会决定自2026年8月28日起委任程根宏教授为独立非执行董事，任期三年。其亦于2019年至2025年期间出任亿帆医药股份有限公司独立董事，自2025年起担任上海爱科百发生物医药技术股份有限公司独立非执行董事。\\n\\n根据股份激励计划，30,000股奖励股份的授出已获全体独立非执行董事批准。程根宏教授已放弃就相关决议的投票权，且不计入董事会法定人数。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662091448","title":"创胜集团医药-B(06628)发布中期业绩 股东应占亏损6734.7万元 同比收窄38.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662091448","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662091448?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:47","pubTimestamp":1787928438,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B(06628)发布截至2026年6月30日止六个月中期业绩，该集团取得收入2359.7万元，同比增长770.42%;公司拥有人应占亏损6734.7万元，同比收窄38.66%;每股亏损0.27元。每股亏损0.16元。公告称，收入增加主要由于对外许可收入及CDMO服务增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488606.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","09939","BK1574","06628","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102126030","title":"创胜集团医药-B2026年中期营收2,360万元同比增774%，经调整净亏损6,500万元收窄34.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102126030","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102126030?lang=zh_cn&edition=full","pubTime":"2026-08-28 21:17","pubTimestamp":1787923020,"startTime":"0","endTime":"0","summary":"创胜集团医药-B公告显示，截至2026年6月30日止六个月，实现收入2,360万元，同比增加774%。收入增长主要来自对外许可收入的新增贡献，以及合同开发与制造等业务的稳步推进。财报同期经调整净亏损6,500万元，相较于去年同期的9,940万元收窄34.6%。经调整净亏损减少，主要是因为管线推进相关的研发投入有所降低。创胜集团医药-B方面表示，公司将继续关注创新药临床试验推进，并加速与全球及区域制药企业展开战略合作。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"创胜集团医药-B2026年中期营收2,360万元同比增774%，经调整净亏损6,500万元收窄34.6%","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122901322","title":"创胜集团医药-B拟于2026年9月9日召开股东特别大会 审议资产购买协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1122901322","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122901322?lang=zh_cn&edition=full","pubTime":"2026-08-25 06:10","pubTimestamp":1787609459,"startTime":"0","endTime":"0","summary":"创胜集团医药-B8月25日公告，公司将于2026年9月9日上午十时在中国苏州星湖街218号生物纳米园B6-501室举行股东特别大会。会议将以普通决议案形式审议并酌情批准以下事项：。根据香港联交所证券上市规则，股东特别大会上所有决议案将以投票方式表决。公司将于2026年9月4日至2026年9月9日暂停办理股份过户登记，以确定有资格出席并投票的股东名单。股东可通过电子会议系统线上观看股东特别大会，但线上参与不计入法定人数且无法线上投票。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126458618","title":"创胜集团医药-B（06628）拟于9月9日召开股东特别大会　9月4日至9日暂停股份过户","url":"https://stock-news.laohu8.com/highlight/detail?id=1126458618","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126458618?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:40","pubTimestamp":1787305244,"startTime":"0","endTime":"0","summary":"创胜集团医药-B8月21日公告称，公司董事会已决定于2026年9月9日（星期三）上午10时在中国苏州星湖街218号生物纳米园B6-501室举行股东特别大会，以审议并酌情批准此前披露的资产购买协议及相关交易事项。为确定有权出席并投票的股东资格，公司将于2026年9月4日（星期五）至2026年9月9日（星期三）暂停办理股份过户登记手续。公司表示，载有交易事项详细信息及股东特别大会通告的通函将适时寄发予全体股东。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658097654","title":"创胜集团拟处置杭州相关资产 聚焦创新药主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2658097654","media":"中国财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658097654?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:54","pubTimestamp":1786528465,"startTime":"0","endTime":"0","summary":"近日，创胜集团医药-B（06628.HK）发布公告称，创胜集团全资子公司杭州奕安济世生物药业有限公司（以下简称“奕安济世”）与药明生物旗下杭州明德生物医药技术有限公司签署资产购买协议，拟作价人民币1.9亿元出售杭州医药合同研发生产机构（CDMO）相关资产，包括目标厂房土地使用权、房屋所有权、生产设备、存量业务合约等资产权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608123839261530.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608123839261530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","06628","BK1574","LNGR","IBBQ","159992","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151387552","title":"创胜集团医药-B(06628)拟于8月28日审议2026年中期业绩及分红事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1151387552","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151387552?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:36","pubTimestamp":1786523798,"startTime":"0","endTime":"0","summary":"创胜集团医药-B（06628）8月12日公告称，公司董事会已排期于2026年8月28日（星期五）召开会议，届时将审议并通过集团截至2026年6月30日止六个月的中期业绩及拟派发的中期股息（如有），并处理其他事项。\n公告并披露，董事会成员包括执行董事、主席兼首席执行官钱雪明博士；非执行董事徐莉博士及徐汉森博士；以及独立非执行董事唐稼松先生和陈瑋女士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657695468","title":"港股午评|恒生指数早盘涨0.15%    国产大模型领涨科技板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2657695468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657695468?lang=zh_cn&edition=full","pubTime":"2026-08-07 12:00","pubTimestamp":1786075220,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.15%，涨37点，报25567点；恒生科技指数涨0.34%。港股早盘成交1412亿港元。国产大模型再度领涨科技板块。MINIMAX-W再涨17.7%，入通首日北水抢筹近27亿港元，ARR呈现阶梯式跳升；智谱涨超17.57% AI模型竞争转向综合比拼，机构看好公司商业化爆发潜力。海清智元再涨超7%，大模型摆脱高性能服务器依赖，降低客户部署成本。新特能源涨10%；协鑫科技涨7.46%。万洲国际跌3.65%，董事会会议延期至8月28日审议中期业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1172","03419","06628","LU0314109678.HKD","LU1166156734.SGD","BK1169","BK1225","03088","03067","LU0320764599.SGD","02833","00975","LU0300738605.USD","FOSUY","LU1235295612.USD","LU0274383008.USD","LU0049112450.USD","BK1554","03423","BK1163","03986","03037","02315","82800","LU0390135332.USD","09067","BK1148","LU0390135506.SGD","03800","02343","09115","03032","LU2039709279.SGD","LU0593848301.USD","BK1179","SG9999011746.SGD","LU0541501648.USD","MCHVY","BK1603","02282","SGXZ90724238.SGD","BK1117","BK1237","SG9999001093.SGD","BK1543","HHImain","BK1103","SG9999001069.SGD","HSTECH","03033","BK1535","SG9999002950.SGD","PCFBY","07226","HK0000252160.HKD","03115","LU0173614495.USD","09088","LU1813983027.USD","LU0052750758.USD","01799","00100","BK1538","00288","02837","07552","00656","LU0708995583.HKD","03417","01392","LU0287142896.SGD","07300","HSI","02513","SG9999014674.SGD","SG9999001226.SGD","SG9999003461.SGD","02800","BK1610","LU0702159699.USD","HK0000500386.USD","07200","LU1023057109.AUD","603986","LU0390135688.USD","SG9999001051.SGD","513600","LU0300738514.USD","LU0359202008.SGD","BK1594","HK0000252152.HKD","07500","LU1328277881.USD","83115","BK1161","MCHmain","BK1521","LU1046422090.SGD","WHGLY","LU0359201885.HKD","LU0541502299.USD","BK1230","688796","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657753693","title":"港股异动 | 创胜集团医药-B(06628)午前涨超11% 拟1.9亿元出售CDMO资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2657753693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657753693?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:27","pubTimestamp":1786073234,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创胜集团医药-B午前涨超11%，截至发稿，涨11.22%，报1.14港元，成交额34.07万港元。消息面上，创胜集团医药-B发布公告，于2026年8月6日，卖方与买方杭州明德生物医药技术有限公司订立资产购买协议，卖方有条件同意出售，而买方有条件同意购买 CDMO资产，总代价为人民币1.9亿元。于二期完成后，本公司将不再于CDMO资产中拥有任何权益。CDMO资产主要包括本集团过往提供CDMO服务所涉及的GMP生产设施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1515","BK1161","09939","KCAI","BK4585","06628","VXUS","BK1574","BK4139","CDMO","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657766762","title":"创胜集团医药-B出售CDMO资产 交易总价1.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657766762","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657766762?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:50","pubTimestamp":1786063800,"startTime":"0","endTime":"0","summary":"8月7日，创胜集团医药-B（06628）发布公告，董事会于2026年8月6日宣布，公司全资附属公司杭州奕安济世生物药业有限公司与买方杭州明德生物医药技术有限公司签订了资产购买协议，出售CDMO资产，交易总价为1.9亿元。交易完成后，公司将不再持有CDMO资产的任何权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073834582979.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073834582979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06628","BK4139","09939","BK1515","159938","CDMO","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142246976","title":"创胜集团医药-B公布7月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1142246976","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142246976?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:56","pubTimestamp":1786006592,"startTime":"0","endTime":"0","summary":"创胜集团医药-B于2026年8月6日发布截至2026年7月31日止的证券变动月报表，综合公告信息如下：。公司已发行股本方面，于7月底普通股已发行股份总数为455,374,999股，其中流通股452,858,499股、库藏股2,516,500股，与上月底相比无新增发行、回购或注销，股本数量保持不变。公告还显示，7月内根据股份激励计划产生了451,500股可在满足归属条件后发行的新股，但本月无实质性新增发行或库藏股变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119575046","title":"创胜集团医药-B（06628）公布解决审计“无法表示意见”最新进展 现金流管理及融资动作持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1119575046","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119575046?lang=zh_cn&edition=full","pubTime":"2026-07-28 07:31","pubTimestamp":1785195086,"startTime":"0","endTime":"0","summary":"7月28日，创胜集团医药-B公告了截至2025年12月31日年度报告所涉“无法表示意见”九大整改措施的最新执行进度，并披露近期在管线合作、技术许可、融资及成本控制等方面的最新数据。年报披露后，公司已获得人民币43百万元新信贷融资，并提取人民币13百万元新银行贷款；同时完成约人民币85百万元银行贷款的续期及展期。公司将继续推进相关合作及融资安排，并按上市规则适时公布进一步信息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120296542","title":"创胜集团医药-B（06628）公布董事会及三大专门委员会最新成员名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1120296542","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120296542?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:55","pubTimestamp":1785164136,"startTime":"0","endTime":"0","summary":"2026年7月27日，创胜集团医药有限公司发布董事名录及其角色与职能公告，披露截至公告日期的董事会及下设三大专门委员会最新组成情况。公告显示，创胜集团医药-B在执行董事、非执行董事及独立非执行董事之间维持明确分工，并通过设立审计委员会、薪酬委员会和提名委员会，强化公司治理机制。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190912895","title":"创胜集团医药-B（06628）调整董事会专责委员会组成　部分符合上市规则","url":"https://stock-news.laohu8.com/highlight/detail?id=1190912895","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190912895?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:52","pubTimestamp":1785163966,"startTime":"0","endTime":"0","summary":"创胜集团医药-B7月27日晚间公告，自2026年7月27日起，公司董事会作出以下调整：。审计委员会与提名委员会成员人数均增至三人，其中大多数为独立非执行董事，已符合上市规则第3.21及3.27A条要求。截至公告日，董事会由五名成员组成，分别为：执行董事、主席兼首席执行官钱雪明博士；非执行董事徐莉博士、徐汉森博士；独立非执行董事唐稼松先生、陈瑋女士。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654046276","title":"创胜集团医药-B(06628.HK)：陈玮获委任为董事会审计委员会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=2654046276","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654046276?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:50","pubTimestamp":1785163838,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06628","BK1574","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653782539","title":"创胜集团医药-B(06628.HK)转仓市值总计2786.14万港元 占比5.77% 从星展银行转出2602.19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653782539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653782539?lang=zh_cn&edition=full","pubTime":"2026-07-22 08:23","pubTimestamp":1784679828,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","06628","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145595503","title":"创胜集团医药-B400万美元向礼来归还两款许可化合物资产","url":"https://stock-news.laohu8.com/highlight/detail?id=1145595503","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145595503?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:28","pubTimestamp":1783423684,"startTime":"0","endTime":"0","summary":"香港 2026年7月7日，创胜集团医药-B（06628）公告称，公司通过全资子公司杭州奕安济世生物药业有限公司与礼来公司签署《第1号修订协议》，将LY-3108653及LY-2950913两项许可化合物及全部相关权利（统称“归还资产”）归还礼来，对价为4.0百万美元（约人民币27.22百万元，按2026年7月7日美元兑人民币汇率1:6.8054计算）。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06628"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984760","title":"创胜集团医药-B(06628.HK)向礼来归还有关归还资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984760","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649984760?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:26","pubTimestamp":1783423585,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1574","BK1161","BK1515","06628"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transcenta.com","stockEarnings":[{"period":"1week","weight":-0.1022},{"period":"1month","weight":-0.0194},{"period":"3month","weight":-0.3399},{"period":"6month","weight":-0.545},{"period":"1year","weight":-0.8016},{"period":"ytd","weight":-0.5236}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"创胜集团医药有限公司是一家从事临床阶段生物制药的发现、研究、开发、制造和业务拓展的投资控股公司。该公司的产品包括MSB2311，TST001，TST005，TST002，TST004，TST003，TST008，MSB0254和TST006。该公司还提供合同开发和生产（CDMO）服务，主要包括工艺开发服务、GMP/cGMP生产服务、细胞株开发服务、样品检测服务、配方优化服务及成药性研究。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.077034},{"month":2,"riseRate":0.2,"avgChangeRate":0.209822},{"month":3,"riseRate":0.6,"avgChangeRate":0.021801},{"month":4,"riseRate":0.4,"avgChangeRate":0.025385},{"month":5,"riseRate":0.4,"avgChangeRate":0.017086},{"month":6,"riseRate":0,"avgChangeRate":-0.133694},{"month":7,"riseRate":0.2,"avgChangeRate":0.238284},{"month":8,"riseRate":0.2,"avgChangeRate":-0.078265},{"month":9,"riseRate":0.4,"avgChangeRate":0.056464},{"month":10,"riseRate":0.2,"avgChangeRate":-0.134792},{"month":11,"riseRate":0,"avgChangeRate":-0.134628},{"month":12,"riseRate":0.2,"avgChangeRate":-0.086836}],"exchange":"SEHK","name":"创胜集团医药-B","nameEN":"TRANSCENTA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供创胜集团医药-B(06628)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"创胜集团医药-B,06628,创胜集团医药-B股票,创胜集团医药-B股票老虎,创胜集团医药-B股票老虎国际,创胜集团医药-B行情,创胜集团医药-B股票行情,创胜集团医药-B股价,创胜集团医药-B股市,创胜集团医药-B股票价格,创胜集团医药-B股票交易,创胜集团医药-B股票购买,创胜集团医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"创胜集团医药-B(06628)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供创胜集团医药-B(06628)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}